RATHER

Rational Therapy for Breast Cancer: Individualized Treatment for Difficult-to-Treat Breast Cancer Subtypes

 Coordinatore UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN 

 Organization address address: BELFIELD
city: DUBLIN
postcode: 4

contact info
Titolo: Mr.
Nome: Donal
Cognome: Doolan
Email: send email
Telefono: +353 1 7161656
Fax: +353 1 7161216

 Nazionalità Coordinatore Ireland [IE]
 Sito del progetto http://www.ratherproject.com
 Totale costo 7˙792˙107 €
 EC contributo 5˙995˙786 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2010-two-stage
 Funding Scheme CP-FP
 Anno di inizio 2011
 Periodo (anno-mese-giorno) 2011-01-01   -   2016-12-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

 Organization address address: BELFIELD
city: DUBLIN
postcode: 4

contact info
Titolo: Mr.
Nome: Donal
Cognome: Doolan
Email: send email
Telefono: +353 1 7161656
Fax: +353 1 7161216

IE (DUBLIN) coordinator 921˙506.00
2    STICHTING HET NEDERLANDS KANKER INSTITUUT

 Organization address address: PLESMANLAAN 121
city: AMSTERDAM
postcode: 1066 CX

contact info
Titolo: Dr.
Nome: Henri
Cognome: Van Luenen
Email: send email
Telefono: +31 20 512 2097
Fax: +31 20 699 1383

NL (AMSTERDAM) participant 1˙499˙587.50
3    OncoMark Limited

 Organization address address: Weston Park 76
city: DUBLIN 14
postcode: -

contact info
Titolo: Dr.
Nome: Mairin
Cognome: Rafferty
Email: send email
Telefono: 35317163666
Fax: +353 1 716 3709

IE (DUBLIN 14) participant 995˙520.00
4    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

 Organization address address: The Old Schools, Trinity Lane
city: CAMBRIDGE
postcode: CB2 1TN

contact info
Titolo: Mr.
Nome: Keith
Cognome: Cann
Email: send email
Telefono: +44 1223 333543
Fax: +44 1223 332988

UK (CAMBRIDGE) participant 906˙227.44
5    Agendia BV

 Organization address address: Science Park 406
city: Amsterdam
postcode: 1098XH

contact info
Titolo: Dr.
Nome: Iris
Cognome: Simon
Email: send email
Telefono: +31 61 326 7875
Fax: +31 20 462 1505

NL (Amsterdam) participant 786˙300.00
6    FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON

 Organization address city: Barcelona
postcode: 8035

contact info
Titolo: Dr.
Nome: Alejandro
Cognome: Piris Gimenez
Email: send email
Telefono: +34 934893021
Fax: +34 934894212

ES (Barcelona) participant 400˙645.12
7    INSTITUT CURIE

 Organization address address: 26, rue d'Ulm
city: PARIS
postcode: 75248

contact info
Titolo: Ms.
Nome: Corinne
Cognome: Cumin
Email: send email
Telefono: +33 1 56 24 66 22
Fax: +33 1 42 34 66 27

FR (PARIS) participant 346˙000.00
8    LUNDS UNIVERSITET

 Organization address address: Paradisgatan 5c
city: LUND
postcode: 22100

contact info
Titolo: Dr.
Nome: Karin
Cognome: Jirström
Email: send email
Telefono: +46 40333088
Fax: +46 40 337063

SE (LUND) participant 140˙000.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

responses    tn    breast    correlations    patients    sequencing    kinome    mutations    ilc    cancer    determination    kinases    therapy    therapies    drugs    genotyping    tumors    genes    cancers    re    activation    anti    subtypes    kinase   

 Obiettivo del progetto (Objective)

'Cancer genotyping has identified a number of correlations between mutations in specific genes and responses to targeted anti-cancer drugs, with many mutations occurring in kinases or downstream signaling components. While there are several ongoing large-scale genome re-sequencing studies for the major cancer types, there is no systematic effort to investigate kinase mutations in distinct biological subtypes of these cancers. Here, we will explore the rate of activation of all kinases (the “kinome”) in two poor-prognosis subtypes of breast cancer for which there are currently no targeted therapies available, namely “triple negative” (TN) breast tumors lacking the estrogen-, progesterone- and HER2 receptors, constituting 15% of breast cancers, and invasive lobular carcinomas (ILC) of the breast, which represent 10% of breast tumors. Thus, we lack effective targeted therapies for one quarter of all breast cancer patients. In this project, we will identify and validate novel kinase targets for therapy for these TN and ILC subtypes. Kinase targets will be identified via a 4-pronged approach: i) direct re-sequencing of the kinome of 150 TN and 150 ILC tumors, ii) determination of abundance and activation status of kinases in these tumors by reverse phase protein array and tissue microarray technologies, iii) determination of copy number variation by SNP arrays, and iv) mRNA quantitation of the kinome using DNA microarrays. Potential kinase targets for therapy will be validated in preclinical models using RNA interference. Finally, we will perform a phase I/II clinical trial to test the efficacy of a selective PI3K inhibitor in breast cancer. The project will deliver proof-of-concept for novel therapeutic interventions, together with matched molecular diagnostic approaches for patient stratification, for up to 25% of breast cancer patients.'

Introduzione (Teaser)

Cancer genotyping has identified a number of correlations between mutations in specific genes and responses to targeted anti-cancer drugs. These cancer-specific mutations may lead to the design of more targeted and personalised treatment.

Altri progetti dello stesso programma (FP7-HEALTH)

DESIRE (2013)

"Development and Epilepsy - Strategies for Innovative Research to improve diagnosis, prevention and treatment in children with difficult to treat Epilepsy"

Read More  

IN-MINDD (2012)

Innovative Midlife Intervention for Dementia deterrence

Read More  

CTCTRAP (2012)

Circulating Tumor Cells TheRapeutic APheresis: a novel biotechnology enabling personalized therapy for all cancer patients

Read More